Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk Neuroblastoma

19 Nov 2013

Abstract excerpt

Chemotherapy induces apoptosis and tumor regression primarily through activation of p53-mediated transcription. Neuroblastoma is a p53 wild type malignancy at diagnosis and repression of p53 signaling plays an important role in its pathogenesis. Recently developed small molecule inhibitors of the MDM2-p53 interaction are able to overcome this repression and potently activate p53 dependent apoptosis in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Cancer-related Molecular Pathways
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24348903
DOI: 10.1371/journal.pone.0079843

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk NeuroblastomaPMID 24348903Read ↗

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroupSemantic proximity Read ↗

Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.Semantic proximity Read ↗

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097Semantic proximity Read ↗

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.Semantic proximity Read ↗

A Three-Gene Expression Signature Model for Risk Stratification of Patients with NeuroblastomaSemantic proximity Read ↗

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.Semantic proximity Read ↗

A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature).Semantic proximity Read ↗

miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastomaSemantic proximity Read ↗

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkersSemantic proximity Read ↗

Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 InhibitionSemantic proximity Read ↗

RNA-Sequencing Reveals Candidate Genes/Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

Genetic discoveries and treatment advances in neuroblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.